PREDNISOLONE, Placebo pMDI to match Budesonide/Formoterol Fumarate pMDI, Placebo MDI match Budesonide, Glycopyronium and Formoterol Fumarate/ Budesonide and Formoterol Fumarate MDI, Symbicort, 160 mikrogram/4,5 mikrogram/puff inhalationsspray, suspension, Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, Budesonide, Glycopyronium and Formoterol Fumarate, SALBUTAMOL
D5982C00007
Phase 3 small_molecule active
Quick answer
PREDNISOLONE, Placebo pMDI to match Budesonide/Formoterol Fumarate pMDI, Placebo MDI match Budesonide, Glycopyronium and Formoterol Fumarate/ Budesonide and Formoterol Fumarate MDI, Symbicort, 160 mikrogram/4,5 mikrogram/puff inhalationsspray, suspension, Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, Budesonide, Glycopyronium and Formoterol Fumarate, SALBUTAMOL for Severe and inadequately controlled asthma is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Severe and inadequately controlled asthma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active